328 First-to-second progression-free survival ratio as a predictor for overall survival in ovarian cancer

Objectives We aimed to evaluate the impact of first-to-second progression free survival (PFS1/PFS2) ratio on overall survival (OS) in patients with ovarian cancer. Methods A retrospective cohort study of all patients with ovarian carcinoma treated in one university-affiliated medical center (2000–7/2017). We included patients who had at-least a second recurrence. We included patients who were initially platinum sensitive, therefore patients with first progression-free survival (PFS) less than 12 months were excluded. Study groups included patients with PFS1/PFS2 P value Results Overall, 65 patients met inclusion criteria. In this cohort, the mean of first PFS was 64.6±54.3 months, and the mean for the second PFS was 20.8±32.4. Overall, 13 (20%) had PFS1/PFS2 Conclusions In patients with ovarian cancer, longer first PFS seems to be associated with longer second PFS. However, first-to-second PFS ratio does not predict OS.